ALK-Abelló (ALK) Q3 2024 earnings summary

Executive summary

• Achieved 18% organic revenue growth in Q3 2024, with strong tablet sales up 29% globally and 27% in Europe, and a significant rebound in JextⓇ sales.

• EBIT margin rose to 23% from 13% year-over-year, driven by sales growth, gross margin improvements, and cost savings.

• Confirmed full-year outlook and advanced ALK+ strategy, including a major in-licensing deal for neffyⓇ nasal spray.

• Patient recruitment completed for phase 1/2 peanut allergy trial, with interim results expected by year-end.

• Ongoing optimization and resource reallocation to high-impact European markets.

Financial highlights

• Q3 revenue: DKK 1,313 million (+18% year-over-year); 9M revenue: DKK 4,038 million (+16%).

• EBIT for 9M 2024 rose 91% to DKK 886 million, with a margin of 21.9%-22%.

• Gross margin improved to 64.3% from 63% year-over-year; free cash flow reached DKK 425 million, up from DKK 51 million.

• DKK 49 million in one-off costs included in 9M EBIT result.

• Q3 net profit: DKK 212 million (+81%); 9M net profit: DKK 645 million (+86%).

Outlook and guidance

• Full-year 2024 outlook unchanged: organic revenue growth of 14%-16% and EBIT margin of 19%-21%.

• Europe expected to lead with double-digit growth; North America and international markets to see single-digit growth.

• Gross margin projected to increase by more than 1 percentage point; R&D expenses to decline to around 10% of revenue.

• Q4 revenue growth anticipated to be lower than Q2/Q3 due to shipment timing and lower North America growth.

• CAPEX projected at DKK 350 million; free cash flow expected to be negative at around DKK 500 million due to neffyⓇ license payment.